Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06245902 · ClinicalTrials.gov registry record · Phase 2
An Acute Migraine Factorial Study
A Phase 2 study, sponsored by Allodynic Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT06245902 is a Phase 2 study that has completed, run by Allodynic Therapeutics. The registered enrollment target is 92 participants.
The verdict
NCT06245902, a Phase 2 study, has completed, sponsored by Allodynic Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
Interventions
- DRUG Matching Placebo
- DRUG Naltrexone and Acetaminophen
- DRUG Naltrexone and Acetaminophen-High Dose
- DRUG Naltrexone Alone (regular dose)
- DRUG Acetaminophen Alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2017-02-18 |
| Est. Completion | 2018-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06245902
The ClinicalTrials.gov registry entry for NCT06245902 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allodynic Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Matching Placebo is the first listed.
NCT06245902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06245902 about?
NCT06245902 is a clinical study titled "An Acute Migraine Factorial Study". The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
What is the current status of trial NCT06245902?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2017-02-18. Estimated completion is 2018-02-08.
What interventions are being tested in trial NCT06245902?
The interventions under investigation include: Matching Placebo (DRUG), Naltrexone and Acetaminophen (DRUG), Naltrexone and Acetaminophen-High Dose (DRUG), Naltrexone Alone (regular dose) (DRUG), Acetaminophen Alone (DRUG).
Who is sponsoring clinical trial NCT06245902?
This trial is sponsored by Allodynic Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.